An interventional study of Instruction in self-referral in Endometrial Cancer, sponsored by Odense University Hospital. Status unknown at 3 sites in Denmark. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-06.
Sponsored by Odense University Hospital · Not applicable, Interventional, and Supportive care
The present study is conducted, to elucidate the value of follow-up examinations in endometrial cancer patients. Specifically the objective is to compare hospital-based follow-up examinations with instruction in self-referral in stage I endometrial cancer patients.
The investigators hypothesize that the intervention, instruction in self-referral, will:
1,325 studies on the registry are indexed under Endometrial Neoplasms; 447 are open to participants now.
This study's enrollment of 211 is above the median of 70 across 941 interventional studies indexed under Endometrial Neoplasms.
Browse Endometrial Neoplasms studies →Odense University Hospital is the lead sponsor of 468 studies on the registry; 109 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients in this arm attend regular follow-up examinations, as is the current standard, at the department of gynecology following surgery.
Instead of regular follow-up examinations, this group is carefully instructed in alarm symptoms that require contact with a physician.
Other: Instruction in self-referral
Also known as: Patient-initiated follow-up
Fear of Cancer Recurrence Inventory (questionnaire)
Time frame: change in score between 1, 10 and 34 months
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Time frame: change in score between 1, 10 and 34 months
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Endometrial cancer Module (EORTC QLQ-EN24)
Time frame: change in score between 1, 10 and 34 months
Posttraumatic Growth Inventory
Time frame: change in score between 1, 10 and 34 months
EQ-5D-5L
Time frame: change in score between 1, 10 and 34 months
Items on Unmet needs from the "Coherence for cancer patients questionnaire"
Time frame: change in score between 1, 10 and 34 months
Disease-free survival
Time frame: 3 years following treatment
Incidence of disease recurrence
Time frame: 3 years following treatment
Resource use at hospital, primary care and use of medicinal products
Resource use at hospital: will be measured through questionnaires completed by relevant personnel. Information on resource use at primary care and use medicinal products: will be collected through the National Insurance Register and the Medicinal Product Register respectively.
Time frame: During the three years following treatment
This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Odense University Hospital